Name | Number of supported studies | Average coverage | |
---|---|---|---|
type II pneumocyte | 9 studies | 29% ± 7% | |
hepatocyte | 6 studies | 55% ± 25% | |
GABAergic neuron | 3 studies | 21% ± 5% | |
astrocyte | 3 studies | 23% ± 4% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 3 studies | 24% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 7480.19 | 226 / 226 | 97% | 116.60 | 395 / 406 |
prostate | 95% | 620.75 | 232 / 245 | 92% | 16.55 | 463 / 502 |
pancreas | 99% | 2108.60 | 326 / 328 | 85% | 12.27 | 152 / 178 |
stomach | 92% | 9752.28 | 332 / 359 | 81% | 9.67 | 232 / 286 |
intestine | 90% | 1342.00 | 866 / 966 | 83% | 9.54 | 435 / 527 |
breast | 95% | 875.28 | 436 / 459 | 74% | 13.52 | 825 / 1118 |
kidney | 99% | 713.21 | 88 / 89 | 58% | 4.47 | 519 / 901 |
lung | 91% | 2354.28 | 524 / 578 | 64% | 18.59 | 743 / 1155 |
thymus | 90% | 318.64 | 585 / 653 | 45% | 2.92 | 275 / 605 |
bladder | 81% | 370.05 | 17 / 21 | 53% | 5.43 | 267 / 504 |
brain | 69% | 192.63 | 1819 / 2642 | 48% | 2.21 | 335 / 705 |
adrenal gland | 95% | 689.14 | 246 / 258 | 19% | 1.17 | 43 / 230 |
uterus | 92% | 296.98 | 156 / 170 | 21% | 1.45 | 97 / 459 |
skin | 84% | 1001.30 | 1522 / 1809 | 26% | 1.70 | 124 / 472 |
ovary | 95% | 341.12 | 171 / 180 | 7% | 0.27 | 29 / 430 |
spleen | 98% | 411.05 | 237 / 241 | 0% | 0 | 0 / 0 |
esophagus | 48% | 117.53 | 693 / 1445 | 49% | 7.71 | 89 / 183 |
adipose | 89% | 332.20 | 1072 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 77% | 220.76 | 1032 / 1335 | 0% | 0 | 0 / 0 |
heart | 41% | 145.03 | 356 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 16% | 33.60 | 146 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 7% | 0.39 | 2 / 29 |
muscle | 6% | 12.18 | 51 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 2% | 0.09 | 1 / 45 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0090181 | Biological process | regulation of cholesterol metabolic process |
GO_0070995 | Biological process | NADPH oxidation |
GO_0006805 | Biological process | xenobiotic metabolic process |
GO_0006629 | Biological process | lipid metabolic process |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005829 | Cellular component | cytosol |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0047822 | Molecular function | hypotaurine dehydrogenase activity |
GO_0050661 | Molecular function | NADP binding |
GO_0004499 | Molecular function | N,N-dimethylaniline monooxygenase activity |
GO_0004497 | Molecular function | monooxygenase activity |
GO_0106294 | Molecular function | NADPH oxidase H202-forming activity |
GO_0004031 | Molecular function | aldehyde oxidase activity |
GO_0050660 | Molecular function | flavin adenine dinucleotide binding |
Gene name | FMO5 |
Protein name | Flavin containing dimethylaniline monoxygenase 5 Flavin-containing monooxygenase (EC 1.-.-.-) Flavin-containing monooxygenase 5 (FMO 5) (Baeyer-Villiger monooxygenase 1) (hBVMO1) (EC 1.14.13.-) (Dimethylaniline monooxygenase [N-oxide-forming] 5) (EC 1.14.13.8) (Dimethylaniline oxidase 5) (NADPH oxidase) (EC 1.6.3.1) |
Synonyms | hCG_1981889 |
Description | FUNCTION: Acts as a Baeyer-Villiger monooxygenase on a broad range of substrates. Catalyzes the insertion of an oxygen atom into a carbon-carbon bond adjacent to a carbonyl, which converts ketones to esters . Active on diverse carbonyl compounds, whereas soft nucleophiles are mostly non- or poorly reactive . In contrast with other forms of FMO it is non- or poorly active on 'classical' substrates such as drugs, pesticides, and dietary components containing soft nucleophilic heteroatoms (Probable) . Able to oxidize drug molecules bearing a carbonyl group on an aliphatic chain, such as nabumetone and pentoxifylline . Also, in the absence of substrates, shows slow but yet significant NADPH oxidase activity . Acts as a positive modulator of cholesterol biosynthesis as well as glucose homeostasis, promoting metabolic aging via pleiotropic effects (By similarity). . |
Accessions | Q9HA79 ENST00000527849.5 E9PJF3 ENST00000578284.5 [P49326-3] P49326 ENST00000533848.2 ENST00000441068.6 [P49326-3] ENST00000254090.9 [P49326-1] ENST00000369272.7 [P49326-2] E9PQ84 E9PP51 ENST00000533174.5 |